Abstract: A polymeric biocidal salt is prepared from two components. The first component comprises a biocidal anionic or cationic monomeric, dendrimeric or polymeric ion. The second component comprises a dendrimeric or polymeric anion or cation having insignificant biocidal activity and a number average molecular weight of at least about 500. The second component will be cationic in nature when the first component is anionic in nature and anionic in nature when the first component is cationic in nature. The salt is further characterized as partially dissolving when exposed to an aqueous medium, thereby: (a) releasing sufficient biocidal ion to exceed the MIC or MBIC of a target bacteria sought to be controlled; and (b) leaving a reservoir of undissolved salt capable of being further dissolved and releasing additional biocidal ion as the biocidal ion is consumed or is otherwise removed from the environment encompassing the target bacteria.

Abstract: The invention provides a nutritional supplement which includes micronutrients to facilitate reduction of cholesterol, and/or reduction of homocystein and/or reduction of low-density lipoprotein-cholesterol (LDL-C) oxidation in humans. In one embodiment the supplement is a multi-vitamin, a mineral supplement which includes at least one component known to reduce cholesterol. The invention further provides a method for tableting one fourth to one half of the daily effective dosage of a phytosterol containing nutritional supplement in a practical sized tablet and a method for reducing blood cholesterol in humans.

Abstract: Disclosed is an emulsified cosmetic which is not sticky, has a long-lasting moisturizing effect, and can realize an excellent shiny sensation after application. Specifically disclosed is an emulsified cosmetic characterized by comprising (A) 0.1 to 15% by mass of a plate-like powder, (B) 0.1 to 30% by mass of an oil having an IOB value of 0.1 to 0.5, (C) 0.01 to 5% by mass of a pulverized agar gel, and (D) 1 to 20% by mass of a moisturizing agent. The plate-like powder preferably has an average particle diameter of 1 to 20 ?m. The pulverized agar gel is one obtained by dissolving agar in water or an aqueous solvent, then allowing the agar solution to cool and solidify to form a gel, and pulverizing the gel.

Abstract: The present invention relates to the compound L-menthyl-N-(2-hydroxyphenyl)carbamate, which is effective against body perspiration odor bacteria, in particular against armpit perspiration odor bacteria, and simultaneously effective as an antioxidant, of the following formula, a method for the production thereof and its use.

Abstract: The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: The present invention provides a method for producing a controlled release microsphere with mean average size greater than 50 ?m, comprising preparing a water-in-oil (w/o) emulsion comprising an inner aqueous layer containing a pharmaceutically effective amount of a biologically active polypeptide with activity similar to parathyroid hormone, and an oil layer containing a polymer substance of poly(lactic-co-glycolic acid) (PLGA), then adding the w/o emulsion into aqueous polyvinyl alcohol (PVA) solution to form a water-in-oil-in-water (w/o/w) double emulsion and then desorbing the solvent in the oil layer. The present invention also provides a controlled release microsphere prepared by the method and use thereof.

Abstract: Cosmetic or dermatological compositions and substrates, containing a NIR light-emitting material, and methods for stimulating healing and/or regenerative properties in the skin, hair and/or scalp are provided.

Abstract: Disclosed are mascara compositions containing a first acrylates copolymer having a relatively low glass transition temperature (Tg) which is less than about 0° C., a second acrylates copolymer having a relatively high glass transition temperature which is between about 0° C. and less than about 60° C., wherein a mixture of the first and second acrylates copolymers has a Tg less than about 20° C., and a solvent. Also disclosed are methods for making the mascara and applying them to keratinous tissue such as eyelashes in order to enhance their appearance.

Abstract: Cosmetic or dermatological compositions and substrates, containing a NIR light-emitting material, and methods for stimulating healing and/or regenerative properties in the skin, hair and/or scalp are provided.

Abstract: Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting ?2 adrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.

Abstract: Methods are provided to enhance deposition of zinc pyrithione.

Abstract: Disclosed are cosmetic compositions comprising at least one latex-film former chosen from at least one random styrene acrylate copolymer and derivatives thereof, and at least one coalescent and/or plasticizer.

Abstract: An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.

Abstract: The present invention relates to systems and methods for generating germicidal compositions for use in a wide variety of settings, including agricultural settings, food production settings, hospitality settings, health care settings, health club settings, exercise facility settings, research based settings, veterinarian settings, medical settings, hydraulic fracturing settings, and/or any setting requiring disinfection.

Abstract: There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.

Abstract: Novel skin moisturizing compositions are applied onto dry skin, particularly mild to moderately dry skin, are non-irritating and contain at least one natural moisturizing factor, butyrospermum parkii, at least one silicone, and Panthenol.

Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the mean Cmax of the antagonist after single dose oral administration of the dosage form after tampering to the mean Cmax of antagonist after single dose oral administration of an intact dosage form is at least 1.5:1.

Abstract: The present invention is to obtain capsules which do not disintegrate in stomach and intestine after orally administrating them and which disintegrate specifically in large intestine. The present invention thus provides a capsule which disintegrates specifically in large intestine, comprising a content comprising a main agent, and a shell, covering the content, comprising a natural water-soluble polymer as a shell base material and chitosan powder dispersing in the natural water-soluble polymer.

Abstract: The present invention provides an active targeting polymer micelle encapsulating a drug, preventing an inappropriate release of a drug which may damage a normal cell. A polymer micelle 100 includes a backbone polymer unit 10 that has a target binding site 11 and a backbone polymer unit 20 that has a drug 14 and is free from the target binding site 11, such polymer units 10 and 20 being disposed in a radial arrangement in a state where the target binding site 11 is directed outward and the drug 14 is directed inward, in which: i) when the micelle is bound to a target 40 while maintaining the radial arrangement, the micelle is taken up into a cell 50 supplying the target 40 through endocytosis, and the drug 14 is released into the cell 50 by collapse of the radial arrangement in the cell 50; and ii) when the radial arrangement collapses in blood 60 before the micelle is bound to a target 40, the unit 20 is excreted through metabolism, to thereby prevent a normal cell from being damaged by the drug 14.